CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-18-00029
Health/Science/Disease Category:
Type 1 Diabetes (T1D)
Short Name:
CTLA Prevention (TN18)
Full Title of Study:
CTLA-4 Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance (AGT) and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus (T1DM)
Phase/Type of Study:
Phase 2
Purpose of Research:
Abatacept is given as an investigational study drug to relatives of someone with type 1 diabetes who have positive diabetes antibodies in an attempt to prevent or delay the onset of type 1 diabetes. See website for more details https://www.trialnet.org/our-research/prevention-studies/abatacept
Eligibility:
1. Be identified as having 2 or more positive autoantibodies, not including mIAA, in the TrialNet Pathway to Prevention Study (TN01). 2. Be aged 6 or older and weigh more than 16 kg. 3. Have normal glucose tolerance by oral glucose tolerance test within 7 weeks of the baseline study visit.
Time Commitment/Requirements:
The treatment period includes 14 study drug infusions over the course of one year. The follow up period includes 2 visits per year and 2 phone calls per year. Compensation provided for all visits.
Primary Investigator:
Roshanak Monzavi, MD
Coordinator Contact Name:
Dan Bisno / Debra Miller, BSN, CDE
Phone Number:
323-361-8641 / 323-361-5963
Email:
dbisno@chla.usc.edu / dmiller@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT01773707